A Cancer Research UK Phase I first in man study of the novel AGC kinase inhibitor AT13148 given orally in patients with advanced solid tumours.
Latest Information Update: 13 Jul 2020
At a glance
- Drugs AT 13148 (Primary)
- Indications Adenocarcinoma; Breast cancer; Colorectal cancer; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man
- 02 Jul 2020 Results published in the Clinical Cancer Research
- 19 Jul 2018 Status changed from recruiting to completed.
- 25 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 May 2017.